Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides commentaries podcast on-demand Webcast and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Share

Program Content

No activities added yet

Activities

<i>EP</i>: Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
ExpressPoints: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 09, 2021

Expires: March 08, 2022

Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 05, 2021

Expires: March 04, 2022

Activities

CDK4/6i for HR+/HER2- MBC
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2021

Expires: August 18, 2022

<i>PodcastPearls</i>: CDK4/6i Slideset
PodcastPearls: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
Podcast Episodes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 24, 2021

Expires: August 23, 2022

Activities

CDK4/6i and PI3Ki in HR+/HER2-
CDK4/6 and PI3K Inhibitors for HR+/HER2- Breast Cancer in the Clinic Today: Thoughts From the Experts
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2021

Expires: March 22, 2022

Abemaciclib in EBC
What to Know About the New Approval for Abemaciclib in Patients With Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 29, 2021

Expires: November 28, 2022

Activities

Managing AEs: Oral Targeted Tx in HR+, HER2– BC
An Interactive Tool for Managing AEs With Oral Targeted Therapies for HR+, HER2– Breast Cancer
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2021

Expires: September 13, 2022

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner